Table 1.
Demographic and clinical characteristics in all cohorts of LVH as well as in controls. P values indicate results from ANOVA analyses between groups of LVH
| LVH | Controls | ||||||
|---|---|---|---|---|---|---|---|
| HOCM | HNCM | AH | p value | HOCM controls | HNCM controls | AH controls | |
| Demographics | N = 33 | N = 9 | N = 13 | N = 33 | N = 9 | N = 13 | |
| Male, n (%) | 13 (39) | 7 (78) | 13 (100) | < 0.001 | 13(39) | 7 (78) | 13 (100) |
| Age (years) | 60.5 ± 17.9 | 47.1 ± 8.3 | 35.3 ± 12.2 | < 0.001 | 66.8 ± 14.8 | 46.8 ± 8.0 | 32.3 ± 11.5 |
| BMI (kg/m2) | 28.0 ± 6.1 | 27.6 ± 4.8 | 29.6 ± 3.8 | 0.231 | 24.1 ± 3.0* | 23.7 ± 3.0 | 22.1 ± 3.5# |
| Clinical | |||||||
| Diabetes, n (%) | 2 (6) | 1 (11) | 0 (0) | 0.530 | 3 (9) | 0 (0) | 0 (0) |
| Manifest hypertension, n (%) | 25 (78) | 0 (0) | 0 (0) | < 0.001 | 22 (67) | 4 (44) | 1 (8) |
| Hypercholesterolemia, n (%) | 17 (53) | 2 (22) | 0 (0) | 0.001 | 12 (36) | 2 (22) | 0 (0) |
| CKD III, n (%) | 9 (28) | 2 (22) | 0 (0) | 0.068 | 5 (15) | 1 (11) | 0 (0) |
| CAD, n (%) | 7 (2) | 1 (11) | 0 (0) | 0.200 | 6 (18) | 1 (11) | 0 (0) |
| PCI, n (%) | 3 (9) | 1 (11) | 0 (0) | 0.611 | 3 (9) | 1 (11) | 0 (0) |
| Class NYHA III–IV, n (%) | 15 (45) | 1 (11) | 0 (0) | 0.003 | 1 (3)* | 0 (0) | 0 (0) |
| MR > I°, n (%) | 12 (36) | 1 (11) | 0 (0) | 0.013 | 9 (27) | 1 (11) | 0 (0) |
ANOVA, analysis of variance; AH, athlete’s heart; BMI, body mass index; CAD, coronary artery disease; CKD III, chronic kidney disease (glomerular filtration rate < 60 ml/min); HNCM, hypertrophic non-obstructive cardiomyopathy; HOCM, hypertrophic obstructive cardiomyopathy; MR, mitral regurgitation; NYHA, New York Heart Association classification; PCI, percutaneous coronary intervention. */#< 0.05/0.01 in comparison with the corresponding LVH group